Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Lender cares about ability to pay interest and principal, not the stock price. Pretty solid liquidity ratios here.
I’m curious what the R&D spend run rate will be for Q1 as a precursor for rest of FY.
Have fun with that
Financials for First Quarter Fiscal Year 2023 Ended June 30, 2022 will be released on August 15, 2022
NORTHVALE, NJ / ACCESSWIRE / August 11, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, announced today that the first quarter financial results of the 2023 fiscal year will be released on Monday, August 15, 2022. Elite's management will host a live conference call Tuesday, August 16th at 11:30 AM EDT to discuss the company's financial and operating results and provide a general business update. Stockholders should submit questions to the company before the call.
Date: August 16, 2022
Time: 11:30 AM EDT
Dial-in numbers: 1-800-346-7359 (domestic)
1-973-528-0008 (international)
Conference number: 98840
Questions: dianne@elitepharma.com
General questions by 5:00 PM EDT on Saturday, August 13, 2022
Financial questions by 7:00 PM EDT on Monday, August 15, 2022
Audio Replay: https://elite.irpass.com/events_presentations
Some companies succeed, some never become successful. C’est la vie.
Lots that we don’t know for sure. Doesn’t look like there will be any shareholder call or letter.
Retail shareholders are not the ones that will drive this stock price.
Going to be funding future acquisitions with debt. I assume they will also look at share dilution as well with so little current shares outstanding. They have a critical cash crunch.
Agreed. Not much going on until end of year/early next year.
And monkeys might fly out of my butt.
There is lots of good about VLD, but pumping false narratives is idiotic.
I’ll avoid responding to several of these questions. Read past cc transcripts for some of these answers. Methadone is completely out of the picture. They don’t even make this anymore and haven’t for years.
Raw materials purchase from 2 1/2 years ago sitting on the shelves. Let’s hope that all doesn’t go to waste.
EBITDA break even moved out to end of 2023 so burning cash until then. Launch customers dragging down margin through 1H 2023 was not resolved as was pushed out 6 months. Margins took massive hit from what they just forecasted 3 months ago. Supply chain issues continue to be a major issue where pricing wasn’t used to offset since it’s a strategic decision to LOWER pricing. This would be a direct contrast to the “no competition” remark made just last quarter.
This was my bigger concern on margins:
“While the company's gross margin for the second quarter was in line with expectations, ongoing supply chain challenges have changed the timing of certain forecasted cost reduction benefits that will impact gross margin in the second half of the year. Bill of material cost savings which were anticipated for the second half of 2022, are now expected to be delayed until the first half of 2023 as the company reduces pre-purchased, higher cost inventory acquired in the first half of 2022 to offset ongoing component shortages and delivery delays. Additionally, these challenges will impact the delivery schedule of its remaining launch customer systems with certain shipments shifting to the third and fourth quarter resulting in more gross margin impact in those quarters than initially forecasted.”
There was zero margin last quarter and 6% this month. Rest of year and first half of next year will be low as well. Cash burn will be high, ever increasing likelihood of need to raise cash.
That’s Q4. Q2 cc is today. 0% margins just mean that much more cash burn.
Big question is whether their gross profit margins will be 0% from launch partner.
I’ll take a sale for 3x today’s price. I’d prefer more, but I’d take 0.15 today and reinvest proceeds elsewhere.
Adderall ER was supposed to be a monster in a 1.3B+ market.
$3 billion market cap?!!?
Elite is the one that wrote this contract as Elite mentioned a few years back. If there are any provisions that are unfavorable or huge risks to Elite that would be extremely embarrassing for a JD CEO.
From last cc, nothing will happen in Israel until later this year, at best.
Companies do it both ways. Many companies take on debt for stock buybacks, not what I would recommend for Elite. Elite needed the term loan to buy the real estate.
Just the approval of a buyback plan would be good news for this stock.
A small buyback with excess cash would go a long way. You can only ping the ask so many times/day with such a plan, but over the course of days/weeks there would be much more attention and support levels would be raised much higher than today’s prices. Doesn’t have to be a huge buyback as the avg daily volume is so small. Plus, it would start getting rid of bloated float.
Stair steps leading down after that fast rise.
Someone is buying in with this sort of consistent uptrend. Question is at what point do they stop buying so aggressively.
Conference call right around the corner. Progress on 30% margin target will be key so they can start to organically offset some of cash burn.
Agreed. Hopefully Lannett keeps driving new contracts. Q1 call just around corner with some insights into back half of year.
I completely agree that the use of IR has been non-existent. There are also plenty of risks that they wouldn’t want to draw attention to - potential repeat of SequestOx and/or ADT failure, Lannett pursuing Adderall IR kicking Elite to curb, etc.
Y/Y organic growth, Loxapine component fix so can grow that product under Burel/Prasco, positive studies completed, FDA filings (not until late Q4 at earliest). Not expecting much other than Q1 financials update at upcoming cc.
5 million out of a billion shares outstanding is minuscule
Shorting banks during rising interest rate environment? Really?
Could be turnover. With all the hiring this year, I believe FTE count was flat to LY.
Lol
They are solid. The biggest concerns should be margins in light of inflation, which will ease near term, but Tesla has pricing power and can adjust accordingly. Separately, I think the new Giga plants are ramping slower than expected, but they’ll continue to improve driving future too and bottom lines.
Interesting, back to your reading comment. I’m sure you mean Total Liabilities & Equity is at $68B, not strictly liabilities.
If you are hinting at liquidity issues, take a look at their positive ratio. Current assets of $31B vs current liabilities of $22B. Not even close to being an issue since the industry average is about 1.0, below Tesla’s measure.
Lease costs are going to be a big liability for any manufacturer and deferred revenue is simply timing.
How is selling an asset illegal? Might want to revisit accounting 101.